HALIFAX, England-- ( BUSINESS WIRE )--Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million. Bluebird on ...

Some of Ascend Performance Materials Inc.’s creditors provided fresh financing to the troubled chemicals firm, giving it time ...

and SK Capital Partners. Per the deal terms, bluebird (NASDAQ:BLUE) stockholders will be entitled to $3.00 per share in cash and an additional payment of $6.84 per share in cash based on a ...

Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital Partners. David Meek, former CEO of Mirati Therapeutics ...

and SK Capital Partners, LP in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird ...

Carlyle (NASDAQ: CG) and SK Capital Partners will acquire bluebird bio (NASDAQ: BLUE), according to a news release. bluebird, ...

Funds advised by SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, completed the acquisition of ...

HALIFAX, England, March 06, 2025--(BUSINESS WIRE)--Funds advised by SK Capital Partners, LP ("SK Capital"), a private investment firm focused on the specialty materials, ingredients, and life ...